---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-024108"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2024-06-17T23:59:59+00:00"
generated_at: "2026-06-01T04:07:14.042600+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Oncocyte appoints Andrea James as CFO, effective June 17, 2024

## Summary
- Andrea James appointed CFO; previously Chief Communications Officer at Axon Enterprise (AXON) and IR roles at Tesla.
- Compensation: $325,000 base salary, 50% target bonus; option for 200,000 shares and 100,000 RSUs (subject to shareholder approval).
- CEO Josh Riggs cites James' experience in capital raising and IR as company nears commercial launch.
- James Liu remains Senior Director, Controller & Principal Accounting Officer.

## SEC filing metadata
- accession: 0001493152-24-024108
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2024-06-17T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315224024108/0001493152-24-024108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315224024108/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-024108
- JSON: https://secwatch.observer/filing/0001493152-24-024108.json
- Plain text: https://secwatch.observer/filing/0001493152-24-024108.txt

## Key facts
- Executive change
  Andrea James was appointed as Chief Financial Officer at Insight Molecular Diagnostics Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On June 17, 2024, the Board of Directors (the “Board”) of Oncocyte Corporation (the “Company”) appointed Andrea James to serve as the Company’s Chief Financial Officer, effective June 17, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315224024108/0001493152-24-024108-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.